GlaxoSmithKline LLC (GSK) plans to lay off 150 Cambridge workers. The layoffs come months after GSK said it had planned to ...

With GSK kicking its research and development engine into high gear in recent years, a shuffling of the scientific priorities ...

Jaguar Land Rover announces job losses, Barclays cuts mortgage rates as low as 3.75% - Latest stock markets updates, business ...

Every single employee at GlaxoSmithKline (GSK) held their breath for today's announcement of how many people would lose their jobs in the company's next round of cuts. There was just one problem ...

GlaxoSmithKline (GSK)'s drug sales reps are steamed that the company's announcement of layoffs of up to 4,000 staff -- expected Thursday -- was not mentioned at their five-day national sales ...

GlaxoSmithKline will this week announce reduced investment in some disease areas and more than 3,000 job cuts as it intensifies its diversification away from its core pharmaceutical business.

GlaxoSmithKline noted that pharmaceutical sales decreased 2% to 4.6 billion pounds in the quarter, hurt by generic competition in the U.S. and a 38% drop in Avandia sales.

GlaxoSmithKline will eliminate 650 positions nationwide as part of a global cost-cutting program. The company is cutting 100 positions in RTP, 100 in Philadelphia and 450 field sales jobs.

LONDON • GlaxoSmithKline said on Wednesday it would shed "several hundred" U.S. commercial jobs and a similar number of research positions as it restructures operations in its biggest market ...

Pharmaceutical giant GlaxoSmithKline is planning to cut hundreds of jobs in the U.S. as part of a corporate restructuring, Bloomberg News reported Monday, citing people familiar with the situation.

Well, the rumors you've been hearing have been confirmed: GlaxoSmithKline (NYSE: GSK) has been slimming down its staff roster. This week, the company told the Wall Street Journal that 700-odd ...

GlaxoSmithKline said June 12 it planned to cut 350 jobs in its research and development departments worldwide as part of a restructuring plan launched last October. "We continue to reshape our R&D ...